Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Helen E. Bryant, Niklas Schultz, Huw D. Thomas et al. · Nature · 2005 · 5.2K citations

Life Sciences, Cancer Biology, Oncology +12

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

George D. Demetri, Margaret von Mehren, Charles D. Blanke et al. · New England Journal of Medicine · 2002 · 4.4K citations · Full text

Medicine, Oncology, Pharmacology +14

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Mark J. Ratain, Tim Eisen, Walter M. Stadler et al. · Journal of Clinical Oncology · 2006 · 1K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

Michael Byrne, Anna K. Nowak · Annals of Oncology · 2004 · 646 citations · Full text

Medicine, Oncology, Thoracic Oncology +9

We Should Desist Using RECIST, at Least in GIST

Robert S. Benjamin, Haesun Choi, Homer A. Macapinlac et al. · Journal of Clinical Oncology · 2007 · 554 citations

Medicine, Oncology, Radiology +17